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costs, we assumed that a treatment was provided to every patient who visited the 
dentist according to the national dental cavities guideline, all related costs were 
obtained from the SOAT fare manual 2011 reported by the government. We multiplied 
the treatment cost for each patient by the total number of dental visits to obtain the 
third-payer cost. We calculated from the patient´s perspective the lost output as a 
result of a reduction of productivity due to dental cavities, using DALYs, multiplied by 
the 2011 current GDP divided by the working-age population. RESULTS: The Economic 
impact for 2011 was USD 67.018.016. This is the result of adding the third-payer cost of 
USD 56.234.161 plus the patient cost of USD 10.783.855. CONCLUSIONS: With this first 
approximation to the economic impact of dental cavities the government can design 
cost-effective oral health policies to reduce its prevalence for Colombia’s population. 
The cost of dental cavities represents 0.02% of 2011 current GDP, this means that on 
average there is an expenditure of USD 1.46 for each Colombian citizen to treat dental 
cavities. Those numbers shows the importance to generate permanent public policies 
to improve the Colombians´ oral health.
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OBJECTIVES: Psoriasis (PSO) is an immune-mediated systemic inflammatory dis-
ease. The therapeutic classes available to treat PSO include biologic drugs. Despite 
rising wholesale acquisition costs of biologics in recent years, little documented 
evidence is available on cost trends from the US managed care perspective. This 
analysis determines the change in healthcare costs for PSO patients to managed care 
organizations. METHODS: Continuously enrolled adult patients with ≥ 2 outpatient 
diagnoses for PSO (ICD-9: 696.1) were selected from the MarketScan Commercial and 
Medicare Supplemental databases if their first biologic prescription date (index date) 
occurred July 2008 through July 2013 and they were biologic naive ≥ 6 months pre-
index. Healthcare costs were based on annual reimbursements for 6 patient cohorts 
initiating biologic therapy from 2008 to 2013. Results were stratified by all-cause vs. 
PSO-related costs and further subdivided into medical inpatient, medical outpatient, 
emergency room, and pharmacy costs. RESULTS: 13,045 patients met the inclusion 
criteria and composed the 6 cohorts. All-cause annual healthcare costs for the years 
2008-2013 were $27,973, $31,507, $35,006, $38,533, $42,289, and $43,431, showing 
increases of 55.3% overall and averaging 11.1% or $3,092 annually. Respective PSO-
related estimated annual costs were $19,991, $21,976, $25,059, $27,853, $31,575, and 
$32,739, showing increases of 63.8% overall and averaging 12.8% or $2,550 annually. 
Although costs increased over time in all categories assessed, the major driver of 
this trend was PSO-related pharmacy costs, predominantly the cost of biologic thera-
pies. These costs were estimated for the years 2008-2013 at $15,871, $18,032, $21,403, 
$22,880, $27,899, and $29,240, showing increases of 84.2% overall and averaging 16.8% 
or $2,674 annually. CONCLUSIONS: For US managed care payers, total healthcare cost 
incurred for patients initiated on biologic therapy for PSO has increased substantially 
in recent years, primarily driven by changes in PSO-related pharmacy costs.
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OBJECTIVES: Injection frequency and costs were examined for aflibercept 2.0 mg and 
ranibizumab 0.5 mg intravitreal injections in patients with neovascular age-related 
macular degeneration (AMD) or central retinal vein occlusion (RVO), and for ranibi-
zumab 0.3 mg injections in patients with diabetic macular edema (DME). METHODS: 
This retrospective US claims study analyzed patients who started first-line treatment 
with ranibizumab or aflibercept (index date [ID]) between 11/18/2011-1/31/2014 for 
AMD, 9/21/2013-7/31/2014 for RVO, and 8/10/2012-1/31/2014 for DME, and met the fol-
lowing criteria: aged ≥ 18y on ID; no bilateral disease; ≥ 12 months continuous coverage 
before ID (baseline period); AMD, RVO or DME diagnosis (ICD-9-CM 362.52, 362.35, or 
362.07) during baseline period or on ID; and 12 months of post-ID follow-up coverage 
without switching therapies. Twelve-month outcomes were number of injections and 
their respective costs. Injection frequency and costs were compared for aflibercept 
vs ranibizumab in multivariate regression models that adjusted for possible con-
founding variables (reference= ranibizumab, all comparisons). RESULTS: In AMD and 
RVO analyses, aflibercept (AMD:N= 316, RVO:N= 55) and ranibizumab (AMD:N= 875; 
RVO:N= 154) recipients had similar unadjusted mean number of injections (AMD:5.6 
vs 5.3, respectively; RVO:4.5 vs 5.0, respectively) and related costs (AMD:$11,372 vs 
$10,856, respectively; RVO:$8219 vs $9733, respectively) at 12 months. In AMD regres-
sion analyses, number and costs of injections were not significantly different between 
aflibercept and ranibizumab (Incidence Rate Ratio [IRR]= 1.05, 95% confidence interval 
[CI]= 0.98-1.13, P= 0.17; Cost Ratio [CR]= 1.04, 95%CI= 0.96-1.14, P= 0.34). Similar results 
were seen for RVO (IRR= 0.91, 95%CI= 0.76-1.10, P= 0.35; CR= 0.89, 95%CI= 0.72-1.11, 
P= 0.31). In DME patients (N= 92), at 12 months, the mean (SD) number of ranibizumab 
0.3 mg injections was 4.4 (2.9) and mean costs were $5289 ($3524). CONCLUSIONS: In 
AMD and RVO patients, injection frequency and costs for aflibercept and ranibizumab 
treatments were similar at 12 months. Mean annual costs of treating DME patients 
with ranibizumab were lower than for AMD and RVO patients.
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to provide an insight regarding interrelationship between the psychological stress as 
one of the contributing factor towards acne among final year pharmacy students at 
International Islamic University Malaysia. METHODS: This cross sectional study was 
conducted by distributing questionnaire among 98 final year students. Information 
on severity of acne and level of stress was collected by using the Global Acne Severity 
Scale (GEA) and the Perceived Stress Scale (PSS) which is a psychological test for 
assessing stress. RESULTS: The results obtained shows that there is positive correla-
tion between acne vulgaris and stress, however it is not significant. The severity of 
the acne such as the open and close comedones, into papules, pustules, and nodules 
and even cysts are also related with several factors which may exacerbate the acne 
conditions. Among those factors are gender and family history, exposure to sunlight, 
diet, lifestyle such as sleep and exercise, skin condition, and also intervention in solv-
ing acne problem. CONCLUSIONS: In conclusion, there is a positive relation between 
acne vulgaris and stress. The acne condition exacerbates in more stressful conditions.
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OBJECTIVES: Incidence and burden data for severe Chronic Hand Eczema (sCHE) 
is limited. In the absence of other means of gathering this data, the study’s pri-
mary objective was to generate estimates for global 1-year period prevalence for 
sCHE. Secondary objectives included an estimate of sufferers whose condition is 
inadequately managed with topical steroids. METHODS: An online survey, aiming 
for nationally representative samples, to 34,765 respondents in USA, UK, France, 
Germany, Japan, India, Brazil, China, recruited via consumer panels. Respondents were 
classified sufferers of sCHE via questions on length of time experiencing symptoms, 
frequency and duration of flares, affected hand surface area, and on severity, using 
the photographic scale developed by Coenraads et al (2005). 147 sufferers meeting 
the qualifying criteria for sCHE completed questions on diagnosis, treatment and 
disease burden. RESULTS: We present our results in the form of descriptive statistics. 
An estimated global1-year period prevalence for sCHE of 0.54% was found, after data 
adjustment to reflect the population of 18-75 year olds by geographical region, and 
projection to total population. This is consistent with the range reported by Diepgen 
et al. (2007) (0.5%-0.7%). Of those classified as sCHE sufferers, 53% reported having 
received a medical diagnosis of sCHE; of these 80.2% had received treatment during 
the study period. 47% of those treated were classified as potentially refractory to topi-
cal steroids. The impact of the disease on the total sufferer population was greatest in 
social activities. CONCLUSIONS: Our results indicate a lower than expected diagnosis 
level of sCHE, given its prevalence and impact on sufferers. We also found that topical 
steroid treatment is unlikely to adequately control symptoms in significant numbers 
of cases of sCHE. We believe our methodology is an innovative alternative, consistent 
with a scientific approach, allowing sizing and understanding of sufferer populations, 
particularly in under-diagnosed conditions.
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OBJECTIVES: Age-related macular degeneration (AMD) is the leading cause of visual 
impairment and blindness in India. A clear understanding of the AMD burden in 
India is essential to meet future demands for eye health care. The current analysis 
aims to evaluate the prevalence of AMD in India through a systematic review of pub-
lished peer-reviewed studies. METHODS: Observational studies reporting the preva-
lence of AMD patients in India were retrieved from an electronic literature search 
in PubMed, Cochrane and EMBASE using the terms age-related macular degenera-
tion, prevalence, and India. Search limits applied included articles in English, in 
human adults, and published since the year 2004. Two researchers independently 
extracted the data along with critical appraisal of the studies. Descriptive statistics 
was performed for comparable outcomes. RESULTS: A total of seven studies met the 
inclusion criteria. The overall prevalence of AMD in India ranges from 1.4% to 3.1%. 
The prevalence was lowest in West India (1.4%) and highest in South India (3.1%). 
We found a higher prevalence of early AMD than late AMD (2.3% vs. 0.6%). AMD was 
more prevalent in rural areas than in urban (2.3% vs.2.1%) and in females than males 
(2.5% vs. 1.9%). The most important demographic factor affecting the prevalence of 
AMD in India appears to be the age (> 65 years). CONCLUSIONS: The prevalence of 
AMD in India has been increasing over the years. It is an emerging challenge for eye 
care and public health professionals in India. Further studies in Indian population 
are warranted to investigate the epidemiological patterns of specific AMD subtypes.
SenSoRy SyStemS diSoRdeRS – cost Studies
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OBJECTIVES: According to the burden disease calculated by Ramirez et. al. (2005), in 
Colombia dental cavities represented the third disease with most DALYs for both gen-
ders in all age groups. Also, the Ministry of Health and Social Protection (2012) reported 
that dental cavities were a leading cause of morbidity in 2011 with 1.360.619 occur-
rences in the health system. Because of this, we decided to determine the economic 
cost of dental cavities in Colombia from the third-payer and patient perspectives for 
year 2011. METHODS: We used the official SISPRO data to get information regarding 
the number of visits per patient who had dental cavities. To calculate the monetary 
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OBJECTIVES: Chronic spontaneous (or idiopathic) urticaria (CSU/CIU) affects 
approximately 0.6% of Taiwanese population. However, little is known about its 
economic impacts in the healthcare system. This study aims to examine the 
costs of CSU/CIU-related treatment in National Health Insurance (NHI) program 
of Taiwan. METHODS: Patients who had at least two outpatient visits (primary/
secondary ICD-9-CM diagnosis code of 708.1, 708.8 or 708.9) with antihistamine 
prescription and occurred at least 42 days apart during 2011 were considered as the 
CSU/CIU cases from the NHI Research database(NHIRD). The cases were matched 
with controls in a 1:4 ratio by age, gender and residential areas from the 2011 NHI 
claims data files for 1-million beneficiaries who were representative of the popula-
tion of Taiwan in 2005. Differences in costs associated with outpatient care, inpatient 
care, emergency care, medical tests and drugs between CSU/CIU cases and their 
comparison groups were predicted by the two-part models and the generalized lin-
ear models. All analysis was stratified by the severity level of CSU/CIU and all costs 
were reported in 2012 New Taiwan dollars (US$1 = NT$30). RESULTS: There were 
145,700 CSU/CIU patients identified as the study cases based on above algorithm, 
of which 83.96% were mild CSU/CIU (dCSU), 15.79% were moderate CSU/CIU (mCSU) 
and 0.25% were severe CSU/CIU (sCSU). The case-comparison analysis showed that 
the NHI costs for patients with dCSU, mCSU and sCSU was 1.23 times, 1.43 times, 
and 1.93 times the costs of the matched controls, respectively. The annual total 
costs attributed to dCSU, mCSU and sCSU were NT$5,730, NT$9,168 and NT$20,522, 
respectively. Costs associated with outpatient care comprised the largest proportion 
of total costs for dCSU patients (60.0%) and for mCSU patients (57.5%). As for sCSU 
patients, the largest components of costs were medical tests (35.0%) and drugs 
(39.4%). CONCLUSIONS: CSU/CIU has substantially impact on direct medical costs 
in Taiwan. The costs increase remarkably with the severity of disease.
PSS17
coSt of canaliculaR laceRation RePaiR in diffeRent hoSPital 
SettingS: a deciSion analySiS
Cannon-Dang E.1, Murchison A.P.2, Bilyk J.R.2, Pizzi L.T.1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Wills Eye Hospital, Philadelphia, PA, USA
OBJECTIVES: To calculate the costs of canalicular laceration (CL) repair at a tertiary 
academic eye care center based on setting and surgeon type. METHODS: A retro-
spective review of hospital records over a 10-year span of all primary CL repairs 
performed at a tertiary eye institution. Input variables included repair setting (minor 
procedure room; MPR vs. operating room; OR), surgeon type (oculoplastic surgeon, 
ophthalmologist, fellow, or resident), stent type (mini-Monoka vs. Crawford), and 
success rate (no epiphora/tearing down face, even with environmental stressors, 
at > 3 months after stent removal). Procedure-level data were used to inform prob-
abilities in a decision analytic model (TreeAge Pro). Costs inputs included supplies 
(institution acquisition prices for drugs and disposable equipment) and personnel 
(institution wages + 30% fringe benefits for surgeon, nurse, nurse anesthetist, anes-
thesiologist, and scheduler). Output of the model was cost per successful repair. 
Univariate sensitivity analyses were performed to test the impact of modifying 
base case inputs ± SD. RESULTS: The estimated cost per procedure was $US323 
in the MPR and $US589 in the OR. The overall success rate in the MPR was 37%, vs. 
88% in the OR (p< 0.0001). The ICER revealed the incremental cost of performing CL 
repair in the OR per success to be $521.56. Within each setting, cost effectiveness of 
oculoplastic surgeons dominated vs. the other surgeon types. Sensitivity analyses 
revealed OR costs to be most sensitive to nurse anesthetist and nurse time, whereas 
MPR costs were most sensitive to ophthalmologist and nurse time. CONCLUSIONS: 
While it was more costly to perform CL repair in the OR, success rates were much 
higher. In addition, success rates were optimal when performed by oculoplastic sur-
geons, suggesting that sub-specialty training maximizes patient outcome. Findings 
are limited to a single institution but call to question whether this procedure should 
be performed in a MPR.
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OBJECTIVES: The objective of this study is to evaluate the cost-effectiveness 
of aflibercept compared to ranibizumab and dexamethasone in the treatment 
of central retinal vein occlusion (CRVO) in Turkey. METHODS: A Markov model 
consisting of health states based on the number of letters read in 15 letter incre-
ments from legal blindness (< 35 letters) to 80+ letters with 30-year timeframe, 
was adapted to the Turkish local setting. Clinical inputs as transitions probabilities 
and incidences of adverse effects were mainly derived from the results of Phase 
III COPERNICUS and GALILEO trials. Economic inputs were based on the expert 
opinion addressing local treatment, monitoring and adverse event management 
algorithms. The primary endpoint was QALYs. Analyses were conducted from the 
Turkish Payer Social Security Institution perspective. All costs were calculated in 
Turkish Liras (TL) and converted to USD using TL/USD currency rate as 2,1 (mid-
2014). RESULTS: The total number of QALYs associated with aflibercept, ranibi-
zumab and dexamethasone were 17.926, 17.194 and 16.928 QALYs respectively; 
resulting in total of 0,101 and 0,368 more QALYs for the treatment with aflibercept 
OBJECTIVES: Equine recurrent uveitis (ERU) is the most common cause of blindness in 
horses world-wide. Several organisms have been associated with ERU, with leptospires 
being the most commonly reported agent. Irrespective of substantial treatment costs, 
the value of affected horses is progressively reduced as ocular involvements (unilateral 
or bilateral visual impairment or blindness) increase. This study aimed to estimate 
the number of horses affected by ERU in the U.S, and approximate the associated 
depreciation due to vision impairment. METHODS: The U.S. horse population size 
was estimated by market research. Published sources allowed the estimation of (1) the 
risk of ERU, (2) the associated visual impairments, accounting for breed differences, 
and (3) the loss of value in function of different ocular involvements and variable 
uses of a horse. Considering U.S. horse breeds and use distributions, the number of 
horses allocated to different levels of vision impairment and associated relative depre-
ciations were calculated. Average value of horses was derived from official sources, 
conservatively excluding very high-priced competition/race horses. RESULTS: It was 
estimated that 576,000 horses are currently affected by ERU in the U.S. Based on ret-
rospective studies, 198,513 and 104,269 of these horses are or are expected to become 
blind in one or both eyes during the next 11 years, respectively. From those horses being 
impaired but maintaining vision, 151,046 horses are unilaterally and 122,172 bilater-
ally affected. Depreciation in horses currently affected by ERU was conservatively 
calculated to $802,482,773. It was estimated that 70% of those losses are caused by 
leptospires. CONCLUSIONS: Approximately 576,000 horses are currently affected by 
ERU in the U.S., from which more than 300,000 horses will become blind in one or both 
eyes. ERU represents a substantial economic burden which conservatively calculates 
to more than $800 MM due to the loss of horse value, not considering treatment costs.
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OBJECTIVES: To estimate the cost of illness associated with diabetic macular edema 
(DME) in 13 countries, with a focus on diagnosis, treatment and cost of advanced 
disease. METHODS: A structured literature review to assess prevalence and cost of 
DME was conducted including Embase, Medline, government and professional asso-
ciation websites. Structured face-to-face or online interviews were conducted with 
378 ophthalmologists experienced in managing DME to determine rates of diagnosis, 
use of drug and laser treatments and frequency of follow-up and monitoring vis-
its. Countries were Belgium, Czech Republic, Finland, France, Germany, Ireland, the 
Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and China. An excel model 
synthesizing data and estimated overall cost of illness was built; costs were converted 
to Euros at 2014 market rates. RESULTS: Across the 13 countries an estimated 5.3 
million people have DME; physicians estimated 32-68% (range between countries) of 
DME patients are undiagnosed, a total of 3.1m people. Annual medical cost of DME 
was estimated to be € 1.2bn, median medical cost per patient was € 918, range from € 46 
(China) to € 4,858 (Switzerland). Productivity loss due to poor vision in DME patients 
costs € 4.7bn, 71% of the total cost of illness. Other cost components were laser and 
drug treatments (mean across countries 17.9%, range 1.4-38.9%), follow-up visits (5.8%, 
2.6-33.9%) and monitoring visits (2.9%, 0.3-15.9%). Diagnosis accounted for 0.3% of 
the total cost (range 0.1-0.9%). Some cost components could not be reliably estimated 
for all countries. CONCLUSIONS: Considerable variation was identified in screening, 
diagnosis and treatment between countries. Despite the availability of effective thera-
pies, physicians reported that current practice fails to identify a substantial proportion 
of patients with DME. Poor vision due to DME results in economic loss that is much 
larger than current spending on therapy. Limitations include use of expert opinion 
and incomplete data; results may not be generalizable outside the countries studied.
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OBJECTIVES: Describing the cost of care for glaucoma patients will lead to a better 
understanding of the disease impact on the healthcare system. Few studies have 
determined healthcare costs associated with glaucoma patients, and even fewer 
examined a commercially insured population. This study sought to characterize 
and compare the glaucoma specific costs and overall healthcare costs before and 
after diagnosis. METHODS: We analyzed a large US commercial claims database to 
identify patients 18 years and older with an initial diagnosis of open-angle glaucoma 
occurring in 2011. Patients with two separate occurrences of open-angle glaucoma 
codes (ICD-9 365.10 or 365.11) were included. Patients were excluded for presence 
of a glaucoma code in the 12 months before their initial diagnosis, other types of 
glaucoma (i.e. angle-closure glaucoma), or other possible causes of vision loss (i.e.: 
cataracts). Outcomes of interest were glaucoma specific and overall healthcare costs 
for the 12-months before (baseline) and 12-months after (follow-up) initial diagnosis. 
Costs consisted of inpatient stays, emergency department visits, general and vision 
related office visits, glaucoma diagnostic tests, glaucoma surgeries, and medica-
tions. Paired t-tests were used to compare baseline and follow-up costs. RESULTS: 
8,575 patients were identified as having newly diagnosed glaucoma in 2011. Mean 
glaucoma specific baseline costs were $107 (95% CI: $102, $112) and follow-up 
costs were $487 (95% CI: $475, $498); resulting in a 4.6-fold increase from baseline 
(p ≤ 0.001). 41% of follow-up glaucoma costs were due to glaucoma medications. 
Mean overall healthcare costs at baseline were $5,405 (95% CI: $5,122, $5,688) and at 
follow-up were $7,106 (95% CI: $6,677, $7,534); resulting in a 1.3-fold increase from 
baseline (p ≤ 0.001). 23.2% of follow-up total healthcare costs were due to medica-
tions. CONCLUSIONS: Glaucoma specific and overall healthcare costs significantly 
increase after glaucoma diagnosis for patients who are commercially insured.
